Search Result
Results for "
hippocampal cells
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0764
-
|
Dibutyryl cAMP sodium; DBcAMP sodium
|
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-17389
-
Genipin
Maximum Cited Publications
22 Publications Verification
(+)-Genipin
|
Autophagy
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research .
|
-
-
- HY-B0534
-
|
Ro111163
|
Monoamine Oxidase
|
Neurological Disease
|
|
Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
-
- HY-B0764A
-
|
Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium
|
PKA
Apoptosis
Reactive Oxygen Species (ROS)
|
Neurological Disease
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-B0696
-
|
NO050328; NO328; TGB
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-14399
-
|
CHF5074; CSP-1103
|
γ-secretase
Apoptosis
|
Neurological Disease
|
|
Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
|
-
-
- HY-148226
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
|
|
20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE induces cell death in organotypic hippocampal slice cultures (OHSCs). 20-5,14-HEDGE enhances ROS production and reduces hypoxia-reoxygenation (HR)-induced apoptosis in ex vivo rat lung slices. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats. 20-5,14-HEDGE can be used for the study of pulmonary vascular signaling and lung injury-related research .
|
-
-
- HY-151527
-
|
|
Akt
PI3K
Epigenetic Reader Domain
|
Neurological Disease
|
|
PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
|
-
-
- HY-113273A
-
|
|
P2X Receptor
|
Neurological Disease
|
|
Diadenosine pentaphosphate pentasodium is an agonist and negative modulator of the P2X1 receptor, an endogenous vasoactive purine dinucleotide that can be isolated from platelets. Diadenosine pentaphosphate pentasodium mediates negative regulation of dendrite growth and number by activating homologous and heterologous P2X1 receptors, which triggers a transient and moderate increase in intracellular calcium levels within dendritic growth cones. Diadenosine pentaphosphate pentasodium is widely present in secretory vesicles such as platelets, chromaffin cells and brain synaptosomes, and exhibits selective activity on dendrite growth of cultured hippocampal neurons, inhibiting only dendrite growth without affecting axon growth. Diadenosine pentaphosphate pentasodium has a weaker ability to compete with RcCHAD for binding to polyP than short-chain polyPs .
|
-
-
- HY-B1095
-
|
|
Progesterone Receptor
Androgen Receptor
Glucocorticoid Receptor
GABA Receptor
|
Neurological Disease
Metabolic Disease
|
|
Chlormadinone acetate is a progestogen with potent progestogenic activity and antiandrogenic effects. Chlormadinone acetate acts on glucocorticoid receptor, progesterone receptor, androgen receptor, and GABAA receptor. Chlormadinone acetate induces endometrial proliferation in estrogen-pretreated rabbits, inhibits testosterone-stimulated growth of the prostate and seminal vesicles in castrated rats, and reduces the thymus and adrenal weights in juvenile rats. Chlormadinone acetate is applicable to research related to diseases such as depression and reproductive metabolic disorders .
|
-
-
- HY-W096638A
-
|
(S)-Glycerolphosphocholine
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Glycerophosphocholine ((S)-Glycerolphosphocholine) is an orally active metabolite that crosses the blood-brain barrier. Glycerophosphocholine acts as a precursor of acetylcholine, a specific marker for phosphatidylcholine breakdown, a major water-soluble storage form of choline, and an intermediate in phosphatidylcholine metabolism. Glycerophosphocholine is specifically elevated in the cerebrospinal fluid of Alzheimer's disease models, and it also promotes growth hormone secretion and fat oxidation. Glycerophosphocholine is also a potential biomarker for breast cancer .
|
-
-
- HY-N1535
-
|
Rubescensine B
|
RIP kinase
Apoptosis
Reactive Oxygen Species (ROS)
JAK
STAT
PI3K
Akt
Sirtuin
Necroptosis
Amyloid-β
|
Neurological Disease
Cancer
|
|
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .
|
-
-
- HY-B0188
-
|
Mianserine
|
Histamine Receptor
Opioid Receptor
ERK
p38 MAPK
|
Neurological Disease
|
|
Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .
|
-
-
- HY-113357
-
|
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
|
-
-
- HY-N0695
-
|
Gomisin-B; Wuweizi ester-B; Schisantherin-B
|
PI3K
Akt
mTOR
GSK-3
Tau Protein
TNF Receptor
Interleukin Related
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
Schisantherin B (Gomisin-B) is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of tau protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression .
|
-
-
- HY-N6043
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
-
- HY-P5883
-
|
tatM2NX
|
TRP Channel
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-M2NX (tatM2NX) is a selective inhibitor targeting human TRPM2 channels and exerts inhibitory effects on ischemic stroke. TAT-M2NX reduces H2O2-induced calcium influx via TRPM2 channels. After traumatic brain injury in mice, TAT-M2NX preserves hippocampal long-term potentiation, improves memory function, and reduces infarct volume after middle cerebral artery occlusion, but it shows no effect on female mice. TAT-M2NX can be used in studies related to traumatic brain injury and ischemic stroke .
|
-
-
- HY-10591
-
|
|
TGF-β Receptor
|
Neurological Disease
|
|
Neuropathiazol, a neuronal differentiation inducer, selectively induces neuronal differentiation of multipotent hippocampal neural progenitor cells .
|
-
-
- HY-122672
-
|
|
FAK
|
Neurological Disease
|
|
Adhesamine, dumbbell-shaped molecule, activates MAPK/FAK pathway. Adhesamine promotes adhesion and growth of mammalian cells. Adhesamine accelerates the differentiation and improves the survival of mice hippocampal neurons in primary culture .
|
-
-
- HY-139192
-
|
NMDAR/TRPM4-IN-2
|
iGluR
TRP Channel
ERK
|
Neurological Disease
|
|
Brophenexin (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin shows neuroprotective activity. Brophenexin prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. Brophenexin protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
|
-
-
- HY-W784030
-
|
|
Amino Acid Derivatives
Biochemical Assay Reagents
Fluorescent Dye
|
Others
|
|
N-TCO-L-lysine is a non-canonical amino acid. N-TCO-L-lysine contains a trans-cyclooctene (TCO) bioorthogonal reactive linker. N-TCO-L-lysine undergoes a bioorthogonal click reaction with SiR-Tz to enable fluorescent labeling of endogenously expressed proteins with site-specific incorporation. When used in combination with SiR-Tz, N-TCO-L-lysine allows super-resolution and live-cell imaging of endogenous proteins .
|
-
-
- HY-115062
-
|
|
Phospholipase
NADPH Oxidase
p38 MAPK
Akt
NF-κB
AP-1
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
MJ-33 lithium salt is a competitive phospholipase A2 (PLA2) inhibitor with an IC50 of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA2 activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA2 (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA2 (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .
|
-
-
- HY-164288
-
|
TDI-006570
|
Cyclic GMP-AMP Synthase
STING
|
Neurological Disease
Inflammation/Immunology
|
|
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
|
-
-
- HY-N4126
-
-
-
- HY-14948
-
|
RWJ-333369
|
Sodium Channel
|
Neurological Disease
|
|
Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .
|
-
-
- HY-W110888
-
|
|
GLUT
|
Neurological Disease
|
|
Brilliant Yellow, a diazo-containing sulfonic aci, is also a potent VGLUT-specific inhibitor. Brilliant Yellow is membrane-impermeable. However, there are some Brilliant Yellow analogs with low cytotoxicity and cell penetration. Brilliant Yellow analogs work on glutamatergic transmission in hippocampal neurons .
|
-
-
- HY-B0764B
-
|
Dibutyryl cAMP; DBcAMP
|
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-120553
-
|
|
Apoptosis
|
Neurological Disease
|
|
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .
|
-
-
- HY-153383
-
|
|
Programmed Cell Death 4 (PDCD4)
|
Cancer
|
|
PDCD4-IN-1(compound 20031600) is a PDCD4 inhibitor with a Kd value of 350 nM, which can promote the expression of BDNF in hippocampal neuron cell HT-22 .
|
-
-
- HY-122672A
-
|
|
FAK
|
Neurological Disease
|
|
Adhesamine diTFA is a dumbbell-shaped molecule that activates the MAPK/FAK pathway. Adhesamine promotes the adhesion and growth of mammalian cells, accelerates the differentiation of primary cultured mouse hippocampal neurons, and enhances their survival rate .
|
-
-
- HY-139192A
-
|
NMDAR/TRPM4-IN-2 free base
|
iGluR
TRP Channel
ERK
|
Neurological Disease
|
|
Brophenexin free base (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin free base shows neuroprotective activity. Brophenexin free base prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. Brophenexin free base protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
|
-
-
- HY-B0764G
-
|
Dibutyryl cAMP sodium; DBcAMP sodium
|
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-128749A
-
|
Calcium D-glucarate tetrahydrate
|
Endogenous Metabolite
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
-
- HY-116586
-
|
|
Sigma Receptor
mAChR
ERK
Amyloid-β
Tau Protein
|
Neurological Disease
|
|
AF710B is an orally effective allosteric agonist for the M1 muscarinic receptor and σ1 receptor. AF710B activates the downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways. AF710B simultaneously improves cognitive function and alleviates the core pathological features of Alzheimer's disease, including Aβ deposition, excessive Tau phosphorylation and neuroinflammation. AF710B is applicable to the research of Alzheimer's disease .
|
-
-
- HY-100743
-
|
2-Amino-4-phosphonobutyric acid
|
mGluR
|
Neurological Disease
Metabolic Disease
|
|
DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system .
|
-
-
- HY-117545
-
|
|
RAR/RXR
|
Cancer
|
|
LE-540 is a selective retinoic acid receptor antagonist for RARβ (Ki=0.22 μM). LE-540 shows potential for use in cancer research, particularly for breast cancer and lung cancer .
|
-
-
- HY-W009300
-
|
4-OHE1
|
Endogenous Metabolite
Estrogen Receptor/ERR
Sirtuin
MDM-2/p53
PDI
Ferroptosis
Reactive Oxygen Species (ROS)
|
Neurological Disease
Metabolic Disease
Cancer
|
|
4-Hydroxyestrone (4-OHE1) is a brain-penetrant estrogen metabolite. 4-Hydroxyestrone shows neuroprotective effects involving increased cytoplasmic localization of p53 resulting from SIRT1-mediated p53 deacetylation. 4-Hydroxyestrone relies on PDI to mediate its protective effect against chemically induced ferroptosis in estrogen receptor-negative cancer cells. 4-Hydroxyestrone inhibits lipid peroxidation and lipid-ROS accumulation. 4-Hydroxyestrone blocks preovulatory luteinizing hormone surges in Rattus norvegicus. 4-Hydroxyestrone can be used for the researches of neurodegeneration, breast cancer and endocrine disease .
|
-
-
- HY-W002438
-
|
|
Biochemical Assay Reagents
Endogenous Metabolite
OAT
Ferroptosis
|
Neurological Disease
Metabolic Disease
|
|
6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
|
-
-
- HY-135525
-
|
|
Dopamine Receptor
Adrenergic Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Agroclavine acts as an agonist of the D1-dopamine receptor and α1-adrenergic receptor. Agroclavine enhances the sensitivity of the brain to magnetic fields; it impairs spatial memory without affecting hippocampal long-term potentiation (LTP). Agroclavine exerts bidirectional regulatory effects on immune activity: it enhances NK cell activity with low toxicity under normal conditions, while it inhibits NK cell activity and exhibits significant cardiac and hepatic toxicity under stress conditions. Agroclavine can be used for research on neuroelectrophysiology, learning and memory, and immunoregulation .
|
-
-
- HY-139008
-
|
|
Glutathione Peroxidase
|
Others
|
|
RC363 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
|
-
-
- HY-100547
-
|
|
iGluR
|
Neurological Disease
|
|
IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo .
|
-
-
- HY-B0764R
-
|
Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)
|
Reference Standards
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-17389R
-
|
(+)-Genipin (Standard)
|
Reference Standards
Autophagy
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Genipin (Standard) is the analytical standard of Genipin. This product is intended for research and analytical applications. Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research .
|
-
-
- HY-112828
-
|
|
DAGL
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation .
|
-
-
- HY-103502
-
CGP7930
1 Publications Verification
|
GABA Receptor
|
Neurological Disease
|
|
CGP7930 (3-(3’,5’-Di-tert-butyl-4’-hydroxy) phenyl-2, 2-dimethylpropanol) is a positive metabotropic GABAB receptor allosteric modulator. CGP7930 enhances the inhibitory effect of l-baclofen on the oscillatory activity of cultured cortical neurons .
|
-
-
- HY-125172
-
|
Polyglutamine Aggregation inhibitor III
|
Huntingtin
|
Others
|
|
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
|
-
-
- HY-107203
-
|
HWA 285
|
Phosphodiesterase (PDE)
Adenosine Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Propentofylline (HWA 285) is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .
|
-
-
- HY-108592
-
|
|
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca 2+ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K + channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .
|
-
-
- HY-149764
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
-
- HY-113357R
-
|
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
|
-
- HY-N16499
-
|
|
Interleukin Related
GDNF Receptor
Trk Receptor
ERK
|
Neurological Disease
Inflammation/Immunology
|
|
Hericene A is an orally active aromatic hericene derivative. Hericene A exhibits anti-inflammatory and neurotrophic activities, and can found in the fruiting bodies of Hericium erinaceus. Hericene A inhibits the secretion of pro-inflammatory mediators. Hericene A promotes axonal growth, neurite branching, neurotrophic factor expression and downstream signal transduction. Hericene A can be used for the research of inflammatory and neurological diseases .
|
-
- HY-139012
-
|
|
Ferroptosis
Glutathione Peroxidase
|
Others
|
|
RC574 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
|
-
- HY-14477
-
|
|
PARP
|
Neurological Disease
|
|
UPF-1035 is a selective PARP-2 inhibitor with an IC50 value of 0.15 μM. UPF-1035 increases CA1 pyramidal cell loss in hippocampal and has neuroprotective activity .
|
-
- HY-N16121
-
|
|
PKC
|
Neurological Disease
|
|
12-Deoxyphorbol 13-isobutyrate (ER272) (DPB), a diterpene, is a PKCα activator. 12-Deoxyphorbol 13-isobutyrate can be isolated from Euphorbia resinifera's latex. 12-Deoxyphorbol 13-isobutyrate facilitates neural stem cells (NSCs) proliferation and activation as well as TGFα release in a reaction dependent on PKCα activation. 12-Deoxyphorbol 13-isobutyrate increases cognitive performance and hippocampal neurogenesis in senescence-accelerated mouse-prone (SAMP8) models. 12-Deoxyphorbol 13-isobutyrate can be used for neurodegenerative diseases research .
|
-
- HY-146351
-
|
|
HDAC
|
Neurological Disease
|
|
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .
|
-
- HY-147681
-
|
|
FGFR
|
Neurological Disease
|
|
SUN13837 is an orally active, blood-brain barrier permeable FGFR modulator and neuroprotective agent. SUN13837 mimics the activity of basic fibroblast growth factor, stimulates intracellular tyrosine phosphorylation of FGFR and signal transduction in neuronal cells, induces neurite outgrowth, and inhibits glutamate-induced neuronal death. SUN13837 can be used in research related to acute cervical spinal cord injury and severe spinal cord injury .
|
-
- HY-P3340
-
|
|
iGluR
|
Neurological Disease
|
|
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .
|
-
- HY-120240
-
|
|
Others
|
Others
|
|
AND-302 is a small molecule anticonvulsant with activity in preventing glutamate- or hydrogen peroxide-induced cell death and decreased neuronal viability in in vitro hippocampal cultures.
|
-
- HY-B0534S1
-
|
Ro111163-d4
|
Monoamine Oxidase
|
Neurological Disease
|
|
Moclobemide-d4 is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
- HY-B0534R
-
|
Ro111163 (Standard)
|
Reference Standards
Monoamine Oxidase
|
Neurological Disease
|
|
Moclobemide (Standard) is the analytical standard of Moclobemide. This product is intended for research and analytical applications. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
- HY-B0534S
-
|
Ro111163-d8
|
Isotope-Labeled Compounds
Monoamine Oxidase
|
Neurological Disease
|
|
Moclobemide-d8 (Ro111163-d8) is the deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
- HY-W670700
-
|
|
MMP
|
Others
|
|
2,5-Dihydroxy-4-methoxyacetophenone (compounds 3) can be isolated from the 80% methanol extract of roots of Cynanchum paniculatum Kitagawa. 2,5-Dihydroxy-4-methoxyacetophenone inhibits glutamate-induced cytotoxicity in hippocampal HT22 cell line . 2,5-Dihydroxy-4-methoxyacetophenone significantly inhibites MMP-13 expression in SW1353 cells, and have the potential for alleviating cartilage degradation .
|
-
- HY-P5487
-
|
|
iGluR
|
Others
|
|
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)
|
-
- HY-149763
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aβ42 agonist-1 is a compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
|
-
- HY-12153
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
JNJ-1930942 is a selective and blood-brain barrier (BBB) penetrant α(7) nAChR positive allosteric modulator.JNJ-1930942 enhances the Choline (HY-B0282)-evoked rise in intracellular Ca 2+ levels and neurotransmission at hippocampal dentate gyrus synapses. JNJ-1930942 reverses the naturally occurring sensory gating deficit in DBA/2 mice .
|
-
- HY-14399R
-
|
CHF5074 (Standard); CSP-1103 (Standard)
|
γ-secretase
Apoptosis
Reference Standards
|
Neurological Disease
|
|
Itanapraced (Standard) is the analytical standard of Itanapraced. This product is intended for research and analytical applications. Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
|
-
- HY-128749AR
-
|
Calcium D-glucarate tetrahydrate (Standard)
|
Endogenous Metabolite
Reference Standards
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
- HY-N0695R
-
|
Gomisin-B (Standard); Wuweizi ester-B (Standard); Schisantherin-B (Standard)
|
Reference Standards
PI3K
Akt
mTOR
GSK-3
Tau Protein
TNF Receptor
Interleukin Related
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
Schisantherin B (Gomisin-B) (Standard) is the analytical standard of Schisantherin B. This product is intended for research and analytical applications. Schisantherin B is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of tau protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression.
|
-
- HY-100743R
-
|
2-Amino-4-phosphonobutyric acid (Standard)
|
mGluR
Reference Standards
|
Neurological Disease
Metabolic Disease
|
|
DL-AP4 (Standard) is the analytical standard of DL-AP4. This product is intended for research and analytical applications. DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system .
|
-
- HY-107203S
-
|
HWA 285-d6
|
Isotope-Labeled Compounds
Phosphodiesterase (PDE)
Adenosine Receptor
|
Neurological Disease
Cancer
|
|
Propentofylline-d6 (HWA 285-d6) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .
|
-
- HY-182597
-
|
|
Imidazoline Receptor
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Tracizoline is an orally active I2-imidazoline receptor agonist. Tracizoline functionally modulates I2-imidazoline receptors, regulates hippocampal FADD cell fate adaptor, attenuates mechanical and thermal hyperalgesia, activates α2A-adrenergic receptors with very weak partial agonism, and induces antidepressant-like activity via 5-HT1A receptor activation. Tracizoline can be used for the research of inflammatory pain, neuropathic pain, and depression .
|
-
- HY-181167
-
|
|
Cholinesterase (ChE)
SOD
|
Neurological Disease
|
|
AChE/BChE-IN-34 is an acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC50s of 5.97 μM and 4.57 μM, respectively. AChE/BChE-IN-34 functions as an antioxidant, oxidative stress inhibitor, reduces MDA levels, and elevates SOD and catalase in hippocampal tissue. AChE/BChE-IN-34 acts as a cognitive function enhancer, improves learning and memory in a Scopolamine (HY-N0296)-induced animal model. AChE/BChE-IN-34 is non-toxic in neuroblastoma cells across a specified concentration range. AChE/BChE-IN-34 can be used for the research of Alzheimer's disease .
|
-
- HY-183352
-
|
|
Cholinesterase (ChE)
Toll-like Receptor (TLR)
p38 MAPK
Interleukin Related
Complement System
|
Neurological Disease
|
BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease .
|
-
- HY-10591R
-
|
|
TGF-β Receptor
Reference Standards
|
Neurological Disease
|
|
Neuropathiazol (Standard) is the analytical standard of Neuropathiazol (HY-10591). This product is intended for research and analytical applications. Neuropathiazol, a neuronal differentiation inducer, selectively induces neuronal differentiation of multipotent hippocampal neural progenitor cells .
|
-
- HY-116153
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
HUHS2002 is a free fatty acid derivative with the ability to enhance α7 cholinergic receptor activity. HUHS2002 enhances whole-cell membrane currents of α7 ACh receptors expressed in Xenopus oocytes in a concentration-dependent manner. The effects of HUHS2002 were blocked in the presence of the Ca2 /calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93. HUHS2002 activated CaMKII in cultured rodent hippocampal neurons, and this activation was abolished by KN-93. HUHS2002 also partially inhibited the activity of protein phosphatase 1 (PP1) in a cell-free PP1 activity assay .
|
-
- HY-183588
-
|
|
EAAT
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
HCM-01 is an Excitatory amino acid transporter 2 (EAAT2) activator with oral effectiveness and blood-brain barrier penetration.HCM-01 binds to the allosteric site of EAAT2, increases EAAT2 expression in astrocytes, enhances glutamate-handling capacity, and modulates glutamate homeostasis.HCM-01 acts as an antioxidant, improves oxidative/antioxidative balance and increases total antioxidant capacity. HCM-01 can be used for the research of Alzheimer's disease .
|
-
- HY-183357
-
|
|
GABA Receptor
5-HT Receptor
Reactive Oxygen Species (ROS)
TNF Receptor
Interleukin Related
COX
NF-κB
IKK
NO Synthase
|
Neurological Disease
Inflammation/Immunology
|
|
GABAAR/5-HT2AR modulator-1 is an orally active and brain-penetrant GABAAR agonist and 5-HT2AR antagonist with Kd values of 0.89 and 0.78 μM. GABAAR/5-HT2AR modulator-1 blocks 5-HT-stimulated IP1 accumulation, inducing a chloride current, reduces LPS (HY-D1056)-induced increases of ROS, NO, TNF-α, IL-6, IL-1β, iNOS, and COX-2 levels. Antidepressant agent 11 dihydrochloride inhibits NF-κB pathway activation by reducing IκBα and p65 phosphorylation and blocking p65 nuclear translocation. GABAAR/5-HT2AR modulator-1 alleviates depression-like behaviors in LPS-challenged and chronic restraint stress-challenged mice, and protects hippocampal neurons against inflammation-mediated damage .
|
-
- HY-181765
-
-
- HY-184011
-
|
|
Serotonin Transporter
Estrogen Receptor/ERR
|
Neurological Disease
|
|
SERT-IN-4 is a brain-penetrant and orally active SERT inhibitor and ERβ agonist with human SERT IC50 of 16.92 nM and human ERβ EC50 of 3.66 nM. SERT-IN-4 inhibits SERT-mediated substrate transport, increases hippocampal serotonin levels, modulates p-CREB and BDNF expression.SERT-IN-4 reduces immobility in CUMS mice, improves social interaction and reduces inactivity in CSDS mice.SERT-IN-4 can be used for the research of major depressive disorder .
|
-
- HY-114613
-
|
|
Amyloid-β
α-synuclein
CGRP Receptor
Amylin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease .
|
-
- HY-182899
-
|
|
PERK
Ras
COX
PD-1/PD-L1
Apoptosis
DNA/RNA Synthesis
Mitochondrial Metabolism
|
Cancer
|
|
DPAP is a p-ERK1/2 inhibitor with an IC50 of 7.85 μM against p-ERK1/2. DPAP inhibits the expression of p-MEK1/2 and disrupts the Ras-ERK signaling pathway. DPAP inhibits the expression of COX-2 in nerve cells. DPAP damages DNA and mitochondria, induces Apoptosis via the mitochondrial pathway, and upregulates PD-L1. DPAP inhibits melanoma metastasis and angiogenesis, and inactivates spinal microglia and astrocytes. DPAP exhibits anti-melanoma activity and can be combined with anti-PD-1 monoclonal antibodies to modify anti-tumor effects. DPAP is applicable for the research of melanoma .
|
-
- HY-183805
-
|
|
5-HT Receptor
FAAH
|
Neurological Disease
|
|
5-HT6R/FAAH modulator 2 is a dual 5-HT6R antagonist and FAAH inhibitor with human 5-HT6R pKi 7.24, human FAAH pIC50 5.47, and blood-brain barrier penetration.5-HT6R/FAAH modulator 2 modulates serotonergic signaling, blocks 5-HT6R function, inhibits endocannabinoid degradation via FAAH catalytic activity suppression.5-HT6R/FAAH modulator 2 exhibits neuroprotective effects against mitochondrial dysfunction, amyloid-β, and glutamate-induced toxicity, reverses memory deficits.5-HT6R/FAAH modulator 2 shows reduced cytotoxicity relative to oxygen-containing lead compounds.5-HT6R/FAAH modulator 2 can be used for the research of Alzheimer's disease .
|
-
- HY-181160
-
|
|
JNK
Wnt
β-catenin
Amyloid-β
Reactive Oxygen Species (ROS)
Beclin1
GSK-3
Beta-secretase
|
Neurological Disease
|
|
JNK3/Wnt/β-catenin modulator-1 is a brain-penetrant JNK3 inhibitor and Wnt/β-catenin activator. JNK3/Wnt/β-catenin modulator-1 decreases Aβ1-42 production and reduced ROS generation. JNK3/Wnt/β-catenin modulator-1 inhibits the activation of JNK and Puma, promotes Beclin-1 expression, reduces GSK-3β and BACE1 expression and activates Wnt/β-catenin signaling. JNK3/Wnt/β-catenin modulator-1 improves cognitive and memory performance, attenuates histopathological brain damage, preserves structure of hippocampal pyramidal cells and cerebral cortical neurons. JNK3/Wnt/β-catenin modulator-1 can be used for the research of Alzheimer's disease .
|
-
- HY-179621
-
|
|
Cholinesterase (ChE)
Amyloid-β
|
Neurological Disease
|
|
EQ-04 is a highly selective positive allosteric modulator (PAM) of α7 nAChR. EQ-04 has no direct inhibitory activity on AChE and BChE. EQ-04 inhibits Aβ aggregation. EQ-04 has safe cytotoxicity and potent neuroprotective activity. EQ-04 can be used for the study of Alzheimer's disease.
|
-
- HY-124057
-
|
|
nAChR
|
Neurological Disease
|
|
RO5126946 is a selective, orally active α7 nAChR allosteric potentiator with EC50 values of 0.06 μM (hα7 nAChR) and 770 nM (α7 nAChR), and it crosses the blood-brain barrier. RO5126946 enhances synaptic transmission and positively modulates GABA-ergic responses by increasing peak current, slowing current decay, and elevating the frequency of spontaneous inhibitory postsynaptic currents, without affecting the recovery of receptors from the desensitized state. RO5126946 not only enhances subthreshold nicotine effects and improves associative learning, but also does not interfere with the original pro-cognitive effects of nicotine. RO5126946 can be used to study cognitive impairments associated with diseases such as Alzheimer's disease and schizophrenia .
|
-
- HY-181549
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Neurological Disease
|
|
PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke .
|
-
- HY-182321
-
|
|
HDAC
|
Neurological Disease
|
|
HDAC2-IN-3 is a selective, orally active, blood-brain barrier permeable HDAC2 inhibitor with an IC50 of 14 nM. HDAC2-IN-3 upregulates histone acetylation levels in cells and in vivo, and enhances long-term potentiation (LTP) in the hippocampus. HDAC2-IN-3 can be used for the research of Alzheimer's disease .
|
-
- HY-W839206
-
|
|
NO Synthase
|
Neurological Disease
|
|
NOS-IN-4 (Compound 3) is a neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 4.00 μM that inhibits nNOS activity. The combined use of alpha-lipoic acid and NOS-IN-4 has a protective effect against MPTP (HY-W114750)-induced dopamine depletion in the mouse brain. NOS-IN-4 can be used for the research of neurological disease .
|
-
- HY-183324
-
|
|
iGluR
Dopamine Transporter
|
Neurological Disease
|
|
AMPA receptor modulator-12 is an orally acrive AMPA receptor positive allosteric modulator. AMPA receptor modulator-12 also exhibits moderate binding affinity for the human dopamine transporter with a Kd of 1.57 μM. AMPA receptor modulator-12 enhances AMPA receptor-mediated ion currents, delays channel deactivation. AMPA receptor modulator-12 prolongs sleep latency, reduces sleep duration, extends forced swimming time, improves rotarod endurance, and alleviates acute sleep deprivation-related behavioral deficits. AMPA receptor modulator-12 does not increase spontaneous locomotion. AMPA receptor modulator-12 can be used for the research of narcolepsy and fatigue-related conditions .
|
-
- HY-15080
-
|
LY 293606
|
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
|
-
- HY-181178
-
|
|
Amyloid-β
|
Neurological Disease
|
|
(Mor-Cor)Ag(III) is a blood-brain barrier-penetrant silver(III) corrole complex that penetrates the blood-brain barrier. (Mor-Cor)Ag(III) scavenges reactive oxygen species induced by Aβ42 and disrupts Aβ42 aggregation, attenuating Aβ42-induced neuronal hyperactivity. (Mor-Cor)Ag(III) can be used for the research of Alzheimer's disease .
|
-
- HY-183944
-
-
- HY-183910
-
|
|
GABA Receptor
Glycine Receptor (GlyR)
|
Neurological Disease
|
|
Pitrazepin is a GABAA receptor antagonist and glycine receptor antagonist. Pitrazepin blocks synaptic GABA action, induces neuronal bursting and reduces inhibitory postsynaptic potentials. Pitrazepin can be used in research on depression and psychosis .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W110888
-
|
|
Biochemical Assay Reagents
|
|
Brilliant Yellow, a diazo-containing sulfonic aci, is also a potent VGLUT-specific inhibitor. Brilliant Yellow is membrane-impermeable. However, there are some Brilliant Yellow analogs with low cytotoxicity and cell penetration. Brilliant Yellow analogs work on glutamatergic transmission in hippocampal neurons .
|
-
- HY-W002438
-
|
|
Biochemical Assay Reagents
|
|
6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5883
-
|
tatM2NX
|
TRP Channel
|
Cardiovascular Disease
Neurological Disease
|
|
TAT-M2NX (tatM2NX) is a selective inhibitor targeting human TRPM2 channels and exerts inhibitory effects on ischemic stroke. TAT-M2NX reduces H2O2-induced calcium influx via TRPM2 channels. After traumatic brain injury in mice, TAT-M2NX preserves hippocampal long-term potentiation, improves memory function, and reduces infarct volume after middle cerebral artery occlusion, but it shows no effect on female mice. TAT-M2NX can be used in studies related to traumatic brain injury and ischemic stroke .
|
-
- HY-P3340
-
|
|
iGluR
|
Neurological Disease
|
|
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .
|
-
- HY-P5487
-
|
|
iGluR
|
Others
|
|
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)
|
-
- HY-K3014C
-
|
|
|
MCE Bi-27 Serum-free Supplement (50×), Insulin-Free is a customized formulation developed by removing insulin from the standard Bi-27 formulation. As a neuronal cell culture supplement, it is specifically designed to support the growth and maintenance of hippocampal neurons and other central nervous system (CNS) neurons in applications where the presence of insulin may interfere with experimental outcomes.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-17389
-
-
-
- HY-W096638A
-
|
(S)-Glycerolphosphocholine
|
Structural Classification
Human Gut Microbiota Metabolites
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Endogenous Metabolite
|
|
Glycerophosphocholine ((S)-Glycerolphosphocholine) is an orally active metabolite that crosses the blood-brain barrier. Glycerophosphocholine acts as a precursor of acetylcholine, a specific marker for phosphatidylcholine breakdown, a major water-soluble storage form of choline, and an intermediate in phosphatidylcholine metabolism. Glycerophosphocholine is specifically elevated in the cerebrospinal fluid of Alzheimer's disease models, and it also promotes growth hormone secretion and fat oxidation. Glycerophosphocholine is also a potential biomarker for breast cancer .
|
-
-
- HY-N1535
-
-
-
- HY-113357
-
-
-
- HY-N0695
-
-
-
- HY-N6043
-
|
|
Structural Classification
Canarium album (Lour.) Rauesch.
Classification of Application Fields
Phenols
Polyphenols
Plants
Burseraceae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
-
- HY-N4126
-
-
-
- HY-128749A
-
-
-
- HY-W009300
-
-
-
- HY-W002438
-
-
-
- HY-135525
-
-
-
- HY-17389R
-
-
-
- HY-113357R
-
|
|
Structural Classification
Monophenols
Microorganisms
Ketones, Aldehydes, Acids
Phenols
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
|
-
-
- HY-N16499
-
-
-
- HY-N16121
-
|
|
Euphorbia triangularis Desf.
Terpenoids
Diterpenoids
Euphorbiaceae
Plants
Source Classification
|
PKC
|
|
12-Deoxyphorbol 13-isobutyrate (ER272) (DPB), a diterpene, is a PKCα activator. 12-Deoxyphorbol 13-isobutyrate can be isolated from Euphorbia resinifera's latex. 12-Deoxyphorbol 13-isobutyrate facilitates neural stem cells (NSCs) proliferation and activation as well as TGFα release in a reaction dependent on PKCα activation. 12-Deoxyphorbol 13-isobutyrate increases cognitive performance and hippocampal neurogenesis in senescence-accelerated mouse-prone (SAMP8) models. 12-Deoxyphorbol 13-isobutyrate can be used for neurodegenerative diseases research .
|
-
-
- HY-W670700
-
-
-
- HY-128749AR
-
|
Calcium D-glucarate tetrahydrate (Standard)
|
Structural Classification
Natural Products
Endogenous metabolite
Source Classification
|
Endogenous Metabolite
Reference Standards
Apoptosis
|
|
D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
-
- HY-N0695R
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0534S1
-
|
|
|
Moclobemide-d4 is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
-
- HY-B0534S
-
|
|
|
Moclobemide-d8 (Ro111163-d8) is the deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
|
-
-
- HY-107203S
-
|
|
|
Propentofylline-d6 (HWA 285-d6) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-113273A
-
|
|
|
Nucleotide Analogs
Adenine Nucleotide
|
|
Diadenosine pentaphosphate pentasodium is an agonist and negative modulator of the P2X1 receptor, an endogenous vasoactive purine dinucleotide that can be isolated from platelets. Diadenosine pentaphosphate pentasodium mediates negative regulation of dendrite growth and number by activating homologous and heterologous P2X1 receptors, which triggers a transient and moderate increase in intracellular calcium levels within dendritic growth cones. Diadenosine pentaphosphate pentasodium is widely present in secretory vesicles such as platelets, chromaffin cells and brain synaptosomes, and exhibits selective activity on dendrite growth of cultured hippocampal neurons, inhibiting only dendrite growth without affecting axon growth. Diadenosine pentaphosphate pentasodium has a weaker ability to compete with RcCHAD for binding to polyP than short-chain polyPs .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0764G
-
|
Dibutyryl cAMP sodium; DBcAMP sodium
|
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: